AAA
SNDX icon

Affinity Asset Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Affinity Asset Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100,000
Closed -$2.54M – 85
2022
Q4 		$2.54M Buy
+100,000
New +$2.33M 1% 32
2022
Q1 		– Sell
-175,000
Closed -$3.83M – 75
2021
Q4 		$3.83M Buy
+175,000
New +$3.23M 1.39% 30

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Affinity Asset Advisors's SNDX Position: Q1 2023 in Review

Affinity Asset Advisors sold out of Syndax Pharmaceuticals (SNDX) in Q1 2023, closing a stake of 100,000 shares — an estimated $2.54M sold.

Affinity Asset Advisors first reported a position in SNDX in Q4 2021 and held it in 2 quarters. The position peaked at $3.83M in Q4 2021. 163 funds tracked by Wall St. Rank hold SNDX as of Q1 2023.

  • Affinity Asset Advisors reported no remaining Syndax Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Affinity Asset Advisors sold 100,000 Syndax Pharmaceuticals shares in Q1 2023, an estimated $2.54M.
  • Affinity Asset Advisors first reported a position in Syndax Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Affinity Asset Advisors's Syndax Pharmaceuticals position peaked at $3.83M in Q4 2021.
  • 163 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2023.

Based on Affinity Asset Advisors's 13F filing for Q1 2023, filed 15 May 2023.